ERBB2 and breast cancer: We identified a total of 3413 patients diagnosed with HER2 IHC0/-low, de novo/recurrent BC between 2010 and 2019, of which 565 (16.30%) and 2,848 (83.70%) were classified as HER2 IHC0 and -low, respectively.